HATSUE FUJINO

Last Updated :2024/06/04

Affiliations, Positions
Hiroshima University Hospital(Medical), Assistant Professor
E-mail
fujino920hiroshima-u.ac.jp
Self-introduction
Expertise: Chronic Viral Hepatitis, Cirrhosis, Fatty Liver, Gastroenterology, Liver Disease, Liver Test Abnormalities

Basic Information

Educational Backgrounds

  • Hiroshima University, Faculty of Medicine, Japan, 2001/04, 2007/03
  • Hiroshima University, Graduate School of Biomedical & Health Sciences , Japan, 2013/04, 2017/03

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Hepatitis virus
  • Cirrhosis

Affiliated Academic Societies

  • The Japanese Society of Internal Medicine
  • The Japanese Society of Gastroenterology
  • The Japan Gastroenterological Endoscopy Society
  • The Japan Society of Hepatology

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2024, Undergraduate Education, Intensive, Introduction to clinical clerkship
  3. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2024, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2024, Undergraduate Education, First Semester, Internal Medicine I

Research Activities

Academic Papers

  1. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15(8), 202304
  2. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
  3. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, CANCERS, 15(3), 202302
  4. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography, JOURNAL OF MEDICAL ULTRASONICS, 50(1), 57-62, 202301
  5. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22(1), 20221222
  6. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151(12), 2278-2290, 20221215
  7. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis, JOURNAL OF MEDICAL ULTRASONICS, 49(3), 443-450, 202207
  8. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection, JOURNAL OF GASTROENTEROLOGY, 57(9), 676-683, 202209
  9. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection., J Gastroenterol, 2022
  10. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis., J Med Ultrason, 2022
  11. HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL., J Infect Dis, 2022
  12. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma., Liver Cancer, 2021
  13. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion., Clin J Gastroenterol, 7(4), 333-337, 2014
  14. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment, PLOS ONE, 17(1), 20220118
  15. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
  16. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene, CASE REPORTS IN GASTROENTEROLOGY, 16(1), 110-115, 2022
  17. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37(3), 592-599, 202203
  18. ★, Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45(6), 607-617, 2015
  19. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 2018
  20. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 2018
  21. ★, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, 2014
  22. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 2017
  23. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, Antiviral Therapy, 23(3), 239-248, 2018
  24. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 2017
  25. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46(12), 1256-1263, 2016
  26. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 2016
  27. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 2016
  28. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25(11), 3272-3281, 2015
  29. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45(6), 656-662, 201506
  30. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45(6), 705-710, 201506
  31. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(4), 726-732, 201504
  32. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44(14), E420-E427, 201412
  33. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44(14), E447-E454, 201412
  34. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44(13), 1320-1328, 201412
  35. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44(7), 740-749, 201407
  36. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29(5), 1035-1042, 201405
  37. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61(130), 323-328, 2014
  38. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28(12), 1834-1841, 201312
  39. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90(12), 1834-1840, 201812
  40. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 201812
  41. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(13), 1118-1130, 201812
  42. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 201904
  43. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
  44. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
  45. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
  46. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 201907
  47. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(4), 341-346, 201908
  48. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
  49. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55(2), 217-226, 2020
  50. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 2020
  51. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(2), 267-270, 202004
  52. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
  53. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
  54. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
  55. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  56. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92(2), 210-218, 202002
  57. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk., Clin J Gastroenterol.
  58. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
  59. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
  60. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98(11), 787-797, 202011
  61. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
  62. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 2021
  63. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
  64. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 2021
  65. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66(4), 1268-1275, 202104
  66. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60(6), 829-837, 2021
  67. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23, 2021
  68. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99(5), 327-335, 202104
  69. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
  70. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
  71. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
  72. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
  73. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100(26), 20210702
  74. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60(13), 2047-2053, 2021
  75. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99(8), 507-517, 2021
  76. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99(8), 491-498, 202107
  77. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
  78. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
  79. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice, CANCERS, 13(16), 202108
  80. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab, MEDICINE, 100(42), 20211022
  81. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma, CANCERS, 14(2), 202201

Invited Lecture, Oral Presentation, Poster Presentation

  1. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, C. Nelson Hayes, Michio Imamura and Hiroshi Aikata, The Liver Meeting 2022 AASLD, 2022/11/22, Without Invitation, English, AASLD, Washington DC
  2. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mice to HepG2/NTCP cells, Hatsue Fujino, Michio Imamura, Hiroshi Aikata, 2022/06/02, Without Invitation, English
  3. Serum autotaxin levels is useful to evaluate fibrosis during entecavir therapy and to predict the development of hepatocellular carcinoma in patients with chronic Hepatitis B., Hatsue Fujino, Kei Morio, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019, Without Invitation, English, Melbourne
  4. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells., Hatsue Fujino, Maiko Namba, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019, Without Invitation, English, Melbourne
  5. Serum Autotaxin Levels Reflect Improvement of Liver Fibrosis in Patients with Chronic Hepatitis B during Entecavir Treatment., Fujino H., Chayama K., AASLD The liver meeting 2018, 2018/11/13, Without Invitation, English, American Association for the study of liver disease, San Francisco
  6. Hepatitis B Core-Related Antigen (HBcrAg) Is a Novel Risk Marker for Hepatocellular Carcinoma during Nucleoside Analoge Treatment., Fujino H., Chayama K., AASLD The liver meeting 2018, 2018/11/13, Without Invitation, English, American Association of the study of liver disease, San Francisco

Awards

  1. 2019, Travel grant award, International HBV Meeting

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2021, 2024
  2. Research Program on Hepatitis, 2021/04/01, 2022/03/31